Enveric Biosciences, Inc. Operating Income Loss

• Enveric Biosciences, Inc. showed an increase of +8.9% in Operating Income Loss from 2024 to 2025.
• This data is from Enveric Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
• XBRL data for this metric is available from 2010 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 15 years of available data (2010 to 2025), Enveric Biosciences, Inc.'s Operating Income Loss has declined by 24,358.4%.
• Historical annual values: Fiscal year 2025: -$8.77 million | Fiscal year 2024: -$9.63 million | Fiscal year 2023: -$16.45 million | Fiscal year 2022: -$27.42 million | Fiscal year 2021: -$64.62 million | Fiscal year 2020: -$5.62 million | Fiscal year 2019: -$2.30 million | Fiscal year 2018: -$7.15 million | Fiscal year 2017: -$10.90 million | Fiscal year 2016: -$5.38 million | Fiscal year 2014: $32.8 thousand | Fiscal year 2013: $27.2 thousand | Fiscal year 2012: -$22.7 thousand | Fiscal year 2011: -$31.4 thousand | Fiscal year 2010: -$35.9 thousand.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026